- A2 Biotherapeutics has raised $80 million in a Series C financing round to support its CAR-T cell therapy programs.
- The funding will accelerate three clinical studies, including trials targeting pancreatic, lung, and colorectal cancers.

A2 Biotherapeutics, Inc., a clinical-stage company specialising in logic-gated cell therapies, has announced the successful close of an $80 million Series C financing round. The investment, led by The Column Group and Samsara BioCapital, will support A2 Bio’s ongoing clinical trials and expand its pipeline of CAR-T cell therapies using its proprietary Tmod platform technology.
The funds will bolster three key programs, including the seamless Phase 1/2 EVEREST-1 and EVEREST-2 trials. These studies focus on targeting challenging cancers such as pancreatic, lung, and colorectal tumors using artificial intelligence (AI)-enabled precision diagnostics through the BASECAMP-1 prescreening platform.
Jim Robinson, Chief Executive Officer of A2 Biotherapeutics, stated, “We are excited by the initial clinical data from our lead programs, which we believe validates our proprietary logic-gate technology approach to solid tumor cancers. This funding will enable us to continue ongoing clinical development of our CAR-T cell therapies as well as fund the potential next phase of development.”
Founded in 2018 and headquartered in Agoura Hills, California, A2 Bio integrates discovery, development, and manufacturing capabilities under one roof. The company plans to allocate Series C funding toward advancing its clinical and preclinical programs, including targeting unmet needs in cancer and beyond.
The EVEREST trials exemplify A2 Bio’s innovative approach, employing the Tmod™ platform to selectively target tumor cells while protecting healthy tissues, a hallmark of its logic-gated technology. The funding positions A2 Biotherapeutics to make strides in addressing significant gaps in cancer treatment.